Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E

被引:33
作者
Bowe, DB
Kenney, NJ
Adereth, Y
Maroulakou, IG
机构
[1] Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Hollings Canc Ctr, Dept Med, Charleston, SC 29425 USA
[3] Hampton Univ, Dept Biol Sci, Hampton, VA 23668 USA
关键词
Neu; mice; mammary gland; cyclin E; cyclin D1;
D O I
10.1038/sj/onc/1205025
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Amplification and/or overexpression of the receptor tyrosine kinase HER2/Neu and the cell cycle regulatory gene cyclin D1 are frequently associated with human breast cancer. We studied the functional significance of cyclin D1 in Neu-induced mammary oncogenesis by developing mice overexpressing either wild-type or mutant Neu in a cyclin D1 deficient background. The absence of cyclin D1 suppresses mammary tumor formation induced by the wild-type or activated mutant form of Neu, which promote multi- and single-step progression of tumorigenesis, respectively. These data indicate that cyclin D1 is preferentially required for Neu-mediated signal transduction pathways in mammary oncogenesis. Significantly, 35% of mutant Neu/cyclin D1(-/-) mice regained mammary tumor potential due to compensation by cyclin E. Thus, shared targets of cyclins D1 and E are important in modulating Neu function in mammary tumorigenesis. Our results imply that the combinatorial inhibition of cyclins D1 and E might be useful in the treatment of malignancies induced by Neu.
引用
收藏
页码:291 / 298
页数:8
相关论文
共 35 条
[1]   TRANSFORMING P21(RAS) MUTANTS AND C-ETS-2 ACTIVATE THE CYCLIN D1 PROMOTER THROUGH DISTINGUISHABLE REGIONS [J].
ALBANESE, C ;
JOHNSON, J ;
WATANABE, G ;
EKLUND, N ;
VU, D ;
ARNOLD, A ;
PESTELL, RG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (40) :23589-23597
[2]   Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes [J].
Amundadottir, LT ;
Leder, P .
ONCOGENE, 1998, 16 (06) :737-746
[3]   neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer [J].
Andrulis, IL ;
Bull, SB ;
Blackstein, ME ;
Sutherland, D ;
Mak, C ;
Sidlofsky, S ;
Pritzker, KPH ;
Hartwick, RW ;
Hanna, W ;
Lickley, L ;
Wilkinson, R ;
Qizilbash, A ;
Ambus, U ;
Lipa, M ;
Weizel, H ;
Katz, A ;
Baida, M ;
Mariz, S ;
Stoik, G ;
Dacamara, P ;
Strongitharm, D ;
Geddie, W ;
McCready, D .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1340-1349
[4]   MULTIPLE INDEPENDENT ACTIVATIONS OF THE NEU ONCOGENE BY A POINT MUTATION ALTERING THE TRANSMEMBRANE DOMAIN OF P185 [J].
BARGMANN, CI ;
HUNG, MC ;
WEINBERG, RA .
CELL, 1986, 45 (05) :649-657
[5]   ONCOGENIC ACTIVATION OF THE NEU-ENCODED RECEPTOR PROTEIN BY POINT MUTATION AND DELETION [J].
BARGMANN, CI ;
WEINBERG, RA .
EMBO JOURNAL, 1988, 7 (07) :2043-2052
[6]   Cyclin D1 in breast cancer [J].
Barnes, DM ;
Gillett, CE .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) :1-15
[7]   Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E [J].
Bortner, DM ;
Rosenberg, MP .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (01) :453-459
[8]   A NEW HIGH-FREQUENCY POLYMORPHISM IN THE HER-2/NEU ONCOGENE IN NORMAL TISSUE AND BREAST-TUMORS [J].
BRISCOE, WT ;
RAY, DB ;
AIRHART, JL ;
RATLIFF, AL ;
SHOCKLEY, EA ;
WHETSELL, L ;
SCHAEFER, FV ;
WILLIAMS, RM .
BREAST CANCER RESEARCH AND TREATMENT, 1993, 28 (01) :45-49
[9]  
Evron E, 2001, CANCER RES, V61, P2782
[10]   MICE LACKING CYCLIN D1 ARE SMALL AND SHOW DEFECTS IN EYE AND MAMMARY-GLAND DEVELOPMENT [J].
FANTL, V ;
STAMP, G ;
ANDREWS, A ;
ROSEWELL, I ;
DICKSON, C .
GENES & DEVELOPMENT, 1995, 9 (19) :2364-2372